Head and Neck Cancer Clinical Trial
Official title:
Evaluation of Fluorescence Imaging in Head and Neck Cancer
Verified date | January 2020 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fluorescent technology continues to advance in the detection of sentinel lymph nodes (SLNs).
Currently, this requires switching from near-infrared light to white light to be able to
identify the fluorescent tissue contrasting with normal surrounding tissue. Currently, no
system has been studied specifically for head and neck sentinel lymph node biopsies using a
hands free goggle system that can visualize white light (normal surgical visualization) and
nearinfrared light (ICG fluorescence) simultaneously. This technology may have implications
on the safety and accuracy of sentinel lymph node biopsy for head and neck mucosal and
cutaneous tumors. Secondarily, this may reduce operative costs by decreasing the amount of
time required to perform the SLNB procedure.
Regarding parathyroid identification, this technology has the potential to identify these
very small glands during procedures they are at risk. These glands are not only at risk of
inadvertent removal if not adequately identified, but may also be at risk if devascularized
by manipulation during the surgical procedure. Therefore, early and accurate identification
may decrease the rate of temporary and permanent hypoparathyroidism and hypocalcemia. This is
not only an issue during thyroid and parathyroid surgery, but during laryngectomy surgery
where the anatomic region these glands are located are often resected to remove at risk lymph
nodes from cancer spread. Therefore, identifying these glands may help preserve parathyroid
function in this patient population as well.
Status | Terminated |
Enrollment | 28 |
Est. completion date | April 15, 2019 |
Est. primary completion date | April 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adults aged 18 years or older will be considered eligible. - Patients with head and neck malignancies, such as melanoma, non-melanoma cutaneous malignancies, or oral cavity squamous cell carcinoma. Patients with central neck pathology including thyroid neoplasms, parathyroid neoplasms, and laryngeal neoplasms undergoing surgical resection. - Candidates for sentinel lymph node biopsy or central neck surgery - Newly diagnosed with clinically node negative head and neck cancer being staged with sentinel lymph node biopsy. - Not pregnant or breast feeding. - Able to understand and willing to sign an IRB-approved written informed consent document. - Able to understand written or spoken English. Exclusion Criteria: - History of allergy to iodide drugs or shellfish (iodine allergy) - Pregnant or breast feeding - Do not fit age criteria - Prisoners - Unable to provide written consent - Contraindications for surgery *Presence of uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of the head and neck, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Receiving any other investigational agents |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure | -Feasibility will be assessed in terms of percentage of patients enrolled for whom peri-tumoral injection with ICG is performed successfully | Up to 1 week after surgery | |
Primary | Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure | -Feasibility will be assessed in terms of percentage patients whom the sentinel and superficial lymph nodes will be detected from the hands free goggle device | Up to 1 week after surgery | |
Primary | Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure | -Feasibility will be assessed in terms of percentage of total lesions identified from the new technique are truly positive as confirmed by biopsy | Up to 1 week after surgery | |
Primary | Feasibility of using a novel fluorescence imaging device to detect a SLN as measured by the ability of the imaging device to identity the SLN by the surgeon during the standard biopsy procedure | -Feasibility will be assessed in terms of the the percentage of total positive SNLs being missed from the new device | Up to 1 week after surgery | |
Primary | Ability of the hands-free goggle system to identify parathryoid glands during central neck surgeries | Up to 1 week after surgery | ||
Secondary | Determine if there is contrast between SLN and surrounding tissues using the novel fluorescence imaging device | Up to 1 week after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |